Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Is Danaher Stock Underperforming the S&P 500?

May 29, 2026 at 10:28 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Washington, the District Of Columbia-based Danaher Corporation (DHR) designs, manufactures, and markets professional, medical, research, and industrial products and services. The company is valued at $127.8 billion by market cap.

Companies worth $10 billion or more are generally described as “large-cap stocks,” and DHR definitely fits that description, with its market cap exceeding this threshold, reflecting its substantial size, influence, and dominance in the diagnostics & research industry. DHR’s competitive strengths come from its portfolio of high-margin, mission-critical tools in biotech, diagnostics, and life sciences. Strong positions in regulated, R&D-heavy markets give it pricing power and resilience, even in downturns.

More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.

Despite its notable strength, DHR shares slipped 25.6% from their 52-week high of $242.80, achieved on Jan. 22. Over the past three months, DHR stock has declined 13.8%, underperforming the S&P 500 Index’s ($SPX) 10% gains during the same time frame.

Shares of DHR fell 20.7% on a YTD basis and dipped 3.9% over the past 52 weeks, underperforming SPX’s YTD gains of 10.5% and 28.5% returns over the last year.

To confirm the bearish trend, DHR is trading below its 200-day moving average since mid-February. It has been trading below its 50-day moving average since late January, with minor fluctuations.

On Apr. 21, DHR shares closed down marginally after reporting its Q1 results. Its adjusted EPS of $2.06 exceeded Wall Street expectations of $1.95. The company’s revenue was $5.95 billion, falling short of Wall Street forecasts of $5.99 billion. DHR expects full-year adjusted EPS in the range of $8.35 to $8.55.

In the competitive arena of diagnostics & research, Revvity, Inc. (RVTY) has taken the lead over DHR, showing resilience with a 4.6% uptick on a YTD basis and 10.8% gains over the past 52 weeks.

Wall Street analysts are bullish on DHR’s prospects. The stock has a consensus “Strong Buy” rating from the 22 analysts covering it, and the mean price target of $242.57 suggests a potential upside of 34.3% from current price levels.

On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.

More news from Barchart

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article